Home Newsfeeds Wolfe Research Upgrades American Airlines Group to Peer Perform

Wolfe Research Upgrades American Airlines Group to Peer Perform

Wolfe Research analyst Scott Group upgrades American Airlines Group (NASDAQ:AAL) from Underperform to Peer Perform.

byBenzinga Newsdesk

March 20, 2023

1 minute read

Wolfe Research analyst Scott Group upgrades American Airlines Group (NASDAQ:AAL) from Underperform to Peer Perform.

Barron’s Top Weekend Stock Picks: AMD, Ford, Accenture And Should Tesla CEO Elon Musk Be Replaced?

By Michael Cohen

December 17, 6:49 PM

Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.

ACN

News

‘Apple Introduces Ask Apple For Developers; A New Series Of Interactive Q&As And One-On-One Consultations’ – Apple

By Benzinga Newsdesk

October 11, 1:04 PM

Apple introduces Ask Apple for developers - Apple Apple today introduced Ask Apple, a new series of interactive Q&As and one-on-one consultations that will provide developers with even more

AAPL

EQRx Announces Acceptance Of Marketing Authorization Application By The European Medicines Agency For Aumolertinib In EGFR-Mutated Non-small Cell Lung Cancer

By Benzinga Newsdesk

December 2, 9:08 AM

Submission is EQRx's first to European Medicines Agency Application is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated

EQRX

Analyst Ratings

Where Apellis Pharmaceuticals Stands With Analysts

By Benzinga Insights

August 24, 9:01 AM

Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

APLS

Wolfe Research Upgrades American Airlines Group to Peer Perform

Related Posts

Barron’s Top Weekend Stock Picks: AMD, Ford, Accenture And Should Tesla CEO Elon Musk Be Replaced?

‘Apple Introduces Ask Apple For Developers; A New Series Of Interactive Q&As And One-On-One Consultations’ – Apple

EQRx Announces Acceptance Of Marketing Authorization Application By The European Medicines Agency For Aumolertinib In EGFR-Mutated Non-small Cell Lung Cancer

Where Apellis Pharmaceuticals Stands With Analysts